6.25
-0.34 (-5.16%)
| Previous Close | 6.59 |
| Open | 6.79 |
| Volume | 60,508 |
| Avg. Volume (3M) | 89,646 |
| Market Cap | 161,111,248 |
| Price / Sales | 11.15 |
| Price / Book | 0.560 |
| 52 Weeks Range |
| Diluted EPS (TTM) | -2.49 |
| Total Debt/Equity (MRQ) | 3.25% |
| Current Ratio (MRQ) | 21.47 |
| Operating Cash Flow (TTM) | -39.28 M |
| Levered Free Cash Flow (TTM) | -26.34 M |
| Return on Assets (TTM) | -22.95% |
| Return on Equity (TTM) | -33.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Contineum Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 1.82% |
| % Held by Institutions | 79.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 31.00 (RBC Capital, 396.00%) | Buy |
| Median | 25.50 (308.00%) | |
| Low | 20.00 (Morgan Stanley, 220.00%) | Buy |
| Average | 25.50 (308.00%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 4.16 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 19 May 2025 | 20.00 (220.00%) | Buy | 4.37 |
| RBC Capital | 15 May 2025 | 31.00 (396.00%) | Buy | 3.94 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 25 Jun 2025 | Announcement | Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 |
| 15 May 2025 | Announcement | Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference |
| 14 May 2025 | Announcement | Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones |
| 28 Apr 2025 | Announcement | Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |